Citadel Advisors’s Sanofi SNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.78M | Buy |
182,200
+125,700
| +222% | +$5.86M | ﹤0.01% | 3439 |
|
|
2025
Q4 | $2.74M | Sell |
56,500
-545,700
| -91% | -$27.1M | ﹤0.01% | 5339 |
|
|
2025
Q3 | $28.4M | Buy |
602,200
+141,000
| +31% | +$6.8M | ﹤0.01% | 1926 |
|
|
2025
Q2 | $22.3M | Buy |
461,200
+394,700
| +594% | +$20.2M | ﹤0.01% | 2014 |
|
|
2025
Q1 | $3.69M | Sell |
66,500
-672,800
| -91% | -$36.4M | ﹤0.01% | 4401 |
|
|
2024
Q4 | $35.7M | Buy |
739,300
+16,700
| +2% | +$849K | 0.01% | 1580 |
|
|
2024
Q3 | $41.6M | Buy |
722,600
+345,000
| +91% | +$18.6M | 0.01% | 1385 |
|
|
2024
Q2 | $18.3M | Sell |
377,600
-319,200
| -46% | -$15.4M | ﹤0.01% | 2081 |
|
|
2024
Q1 | $33.9M | Sell |
696,800
-23,400
| -3% | -$1.14M | 0.01% | 1541 |
|
|
2023
Q4 | $35.8M | Buy |
720,200
+13,300
| +2% | +$650K | 0.01% | 1454 |
|
|
2023
Q3 | $37.9M | Buy |
706,900
+376,100
| +114% | +$20.1M | 0.01% | 1301 |
|
|
2023
Q2 | $17.8M | Buy |
330,800
+54,000
| +20% | +$2.91M | ﹤0.01% | 1997 |
|
|
2023
Q1 | $15.1M | Sell |
276,800
-164,300
| -37% | -$7.99M | ﹤0.01% | 2265 |
|
|
2022
Q4 | $21.4M | Sell |
441,100
-1,700
| -0.4% | -$74.6K | 0.01% | 1900 |
|
|
2022
Q3 | $16.8M | Buy |
442,800
+127,200
| +40% | +$5.67M | ﹤0.01% | 2080 |
|
|
2022
Q2 | $15.8M | Buy |
315,600
+46,100
| +17% | +$2.45M | ﹤0.01% | 2102 |
|
|
2022
Q1 | $13.8M | Buy |
269,500
+88,000
| +48% | +$4.54M | ﹤0.01% | 2480 |
|
|
2021
Q4 | $9.09M | Buy |
181,500
+119,900
| +195% | +$5.93M | ﹤0.01% | 3234 |
|
|
2021
Q3 | $2.97M | Buy |
61,600
+17,700
| +40% | +$900K | ﹤0.01% | 5389 |
|
|
2021
Q2 | $2.31M | Sell |
43,900
-215,000
| -83% | -$11.2M | ﹤0.01% | 6230 |
|
|
2021
Q1 | $12.8M | Buy |
258,900
+152,300
| +143% | +$7.32M | ﹤0.01% | 2607 |
|
|
2020
Q4 | $5.18M | Buy |
106,600
+45,000
| +73% | +$2.22M | ﹤0.01% | 3618 |
|
|
2020
Q3 | $3.09M | Sell |
61,600
-16,300
| -21% | -$839K | ﹤0.01% | 3936 |
|
|
2020
Q2 | $3.98M | Sell |
77,900
-38,500
| -33% | -$1.87M | ﹤0.01% | 3402 |
|
|
2020
Q1 | $5.09M | Sell |
116,400
-61,400
| -35% | -$2.94M | ﹤0.01% | 2676 |
|
|
2019
Q4 | $8.93M | Buy |
177,800
+101,700
| +134% | +$4.76M | ﹤0.01% | 2324 |
|
|
2019
Q3 | $3.53M | Sell |
76,100
-89,900
| -54% | -$3.88M | ﹤0.01% | 3599 |
|
|
2019
Q2 | $7.18M | Buy |
166,000
+30,700
| +23% | +$1.31M | ﹤0.01% | 2592 |
|
|
2019
Q1 | $5.99M | Buy |
135,300
+40,200
| +42% | +$1.72M | ﹤0.01% | 2744 |
|
|
2018
Q4 | $4.13M | Sell |
95,100
-11,000
| -10% | -$485K | ﹤0.01% | 3056 |
|
|
2018
Q3 | $4.74M | Buy |
106,100
+9,500
| +10% | +$406K | ﹤0.01% | 3087 |
|
|
2018
Q2 | $3.87M | Buy |
96,600
+3,500
| +4% | +$138K | ﹤0.01% | 3119 |
|
|
2018
Q1 | $3.73M | Buy |
93,100
+65,000
| +231% | +$2.7M | ﹤0.01% | 2835 |
|
|
2017
Q4 | $1.21M | Sell |
28,100
-18,300
| -39% | -$844K | ﹤0.01% | 4385 |
|
|
2017
Q3 | $2.31M | Buy |
46,400
+16,800
| +57% | +$813K | ﹤0.01% | 3240 |
|
|
2017
Q2 | $1.42M | Sell |
29,600
-50,900
| -63% | -$2.43M | ﹤0.01% | 3609 |
|
|
2017
Q1 | $3.64M | Sell |
80,500
-26,800
| -25% | -$1.14M | ﹤0.01% | 2379 |
|
|
2016
Q4 | $4.34M | Buy |
107,300
+44,600
| +71% | +$1.76M | ﹤0.01% | 2147 |
|
|
2016
Q3 | $2.4M | Buy |
62,700
+10,000
| +19% | +$401K | ﹤0.01% | 2757 |
|
|
2016
Q2 | $2.21M | Buy |
+52,700
| New | +$2.16M | ﹤0.01% | 2640 |
|
Other funds holding SNY
MIP
Citadel Advisors's SNY Position: Q1 2026 in Review
Citadel Advisors increased its Sanofi (SNY) stake by 19% in Q1 2026, buying an estimated $11M and bringing the position to 1,487,970 shares worth $71.7M. The position accounts for 0.01% of the portfolio, ranked #1058.
Citadel Advisors first reported a position in SNY in Q2 2013 and has held it in 38 quarters since. 737 funds tracked by Wall St. Rank hold SNY as of Q1 2026.
- Citadel Advisors held 1,487,970 shares of Sanofi worth $71.7M as of Q1 2026.
- Citadel Advisors bought 235,434 Sanofi shares in Q1 2026, an estimated $11M.
- Sanofi made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1058 holding.
- Citadel Advisors first reported a position in Sanofi in Q2 2013 and has held it in 38 quarters since.
- 737 funds tracked by Wall St. Rank held Sanofi as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.